CIALIS 5 MG
TADALAFIL : 5 MG · DIN 02296896 · ELI LILLY CANADA INC
Health Canada status: MARKETED
What is CIALIS?
CIALIS 5 MG contains TADALAFIL : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 02296896, held by ELI LILLY CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 18-Jan-2008. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CIALIS used for?
Treatment of erectile dysfunction (ED), signs and symptoms of benign prostatic hyperplasia (BPH), and the combination of ED and BPH (ED/BPH).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02296896 |
|---|---|
| Brand name | CIALIS |
| Generic / active ingredient | TADALAFIL : 5 MG |
| Manufacturer | ELI LILLY CANADA INC |
| Strength | 5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | G04BE08 TADALAFIL |
| AHFS class | 24:12.12 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 18-Jan-2008 |
| Original market date | 2008-01-18 00:00:00 |
How is it administered?
ED: 10-20 mg on-demand or 2.5-5 mg once daily. BPH or ED/BPH: 5 mg once daily. Once daily dosing provides continuous plasma levels. Dose adjustments may be needed with CYP3A4 inhibitors.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not specified in the provided text (Table of Contents points to page 22, but text ends at page 12).
How is it supplied?
Not explicitly detailed in provided text (mentions bottles of 100 in general practice, but text only lists strengths).
Contraindications
Co-administration with any form of organic nitrates or guanylate cyclase stimulators (e.g. riociguat). Patients with previous NAION. Hypersensitivity to tadalafil or any tablet component.
Warnings and precautions
Potential cardiac risk with sexual activity; priapism (seek help for erections >4h); sudden vision/hearing loss; symptomatic hypotension with alpha-blockers; caution in bleeding disorders.
Is TADALAFIL in shortage in Canada?
A Canadian shortage report is on file for this molecule: Anticipated — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code G04BE08 TADALAFIL. 67 of 104 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-TADALAFIL | 10 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02515997 |
| ACH-TADALAFIL | 20 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02516004 |
| ACH-TADALAFIL | 5 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02515989 |
| AG-TADALAFIL | 20 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02481421 |
| AG-TADALAFIL | 5 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02481405 |
| APO-TADALAFIL | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02422107 |
| APO-TADALAFIL | 2.5 MG | TABLET | APOTEX INC | MARKETED | DIN 02422085 |
| APO-TADALAFIL | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 02422115 |
| APO-TADALAFIL | 5 MG | TABLET | APOTEX INC | MARKETED | DIN 02422093 |
| APO-TADALAFIL PAH | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 02421933 |
Who else supplies TADALAFIL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TADALAFIL appears in 686 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.